Decoding the Global Biopharma Network: How Data-Driven Partnering Is Redefining Japan’s Next Move

Partnerships have become the new currency of pharmaceutical innovation — and Japan is racing to keep pace. As billion-dollar alliances and data-driven strategies reshape the global landscape, success now depends less on laboratory breakthroughs and more on reading the market: knowing when to collaborate, where to invest, and how to turn science into scalable opportunity. At BIO Japan 2025, Prem Keswani, Head of APAC (Japan) Consulting at Citeline | Evaluate, shared data-driven insights on how global licensing, M&A, and innovation trends are reshaping the pharmaceutical landscape. Drawing on live analytics from Biomedtracker, he illustrated what Japanese pharma leaders can do to stay competitive amid fast-shifting market dynamics.

Prem Keswani (featured): shared how data-driven insights from Citeline | Evaluate’s Biomedtracker reveal the forces reshaping global biopharma partnerships, licensing, and M&A — and what Japan’s pharma leaders must do to compete globally. Image: GeneOnline

Partnerships Powering the Industry: $192 Billion in 2024 Deals

According to Citeline’s data, global biopharma dealmaking reached a potential total value of USD 191.9 billion in 2024, up 3 percent from the previous year even as the number of transactions dipped 4 percent. “Activity is consolidating into larger, more strategic alliances,” Keswani explained. “The second quarter saw the highest volume — 187 agreements — while the fourth quarter delivered the greatest total value, around $73 billion.”

These figures underscore a clear shift: fewer but higher-impact partnerships driven by targeted therapeutic focus and technology convergence. Across all categories, oncology remained the dominant field, representing roughly 40 percent of total deal value and accounting for 31 individual partnerships worth more than $1 billion each.

“Oncology continues to anchor the global partnering landscape,” Keswani noted. “Its high unmet need and rapid innovation cycles — especially around ADC, CAR-T, and immune-cell therapy — make it an enduring magnet for capital.”

He cited Prime Medicine’s $3.6 billion collaboration with Bristol Myers Squibb as an emblematic case: Prime contributes its proprietary gene-editing platform, while BMS handles manufacturing and clinical development. “This type of structured collaboration — where scientific design meets scale manufacturing — is increasingly the model for next-generation partnerships,” Keswani said.

M&A: Consolidation in Motion

Beyond licensing, M&A activity also reflects industry realignment. Citeline tracked multiple transactions exceeding $1 billion, mirroring 2023 volumes but with a 4 percent increase in total value. Among them, Catalent’s $16.5 billion acquisition stood out — representing nearly 45 percent of all first-quarter deal value.

Keswani explained that such mega-deals highlight three underlying dynamics:

1. Uncertainty and financing pressure — companies seek stable pipelines through acquisition.
2. Manufacturing capacity and quality — as seen in Catalent’s appeal to large pharma.
3. Long-term synergy with R&D portfolios — reflecting strategic rather than opportunistic consolidation.

“While the number of deals above the billion-dollar mark stayed constant,” he said, “the rationale shifted from short-term expansion to building durable platforms for innovation.”

Oncology Dominance and the Data Behind It

Oncology’s influence extends beyond quantity. Citeline’s valuation model estimated oncology-related assets at $76.8 billion, with partnerships increasingly concentrated in first-in-class or platform-based programs. “It’s not just the number of deals,” Keswani emphasized. “The depth of investment and scientific novelty are what drive momentum.”

He pointed to the recent MorphoSys acquisition, where an advanced oncology pipeline and multi-layered partnership network drew global investor attention. “These examples show that investors reward not only promising molecules but also organizations capable of orchestrating external innovation effectively,” he added.

Why Scenario Analysis and Data-Driven Evaluation Matter

For Keswani, data is not simply retrospective — it’s predictive. “To make smarter partnering decisions, companies need structured scenario analysis, stakeholder awareness, and benchmarking,” he said. “The key is moving from anecdotal decision-making to evidence-based foresight.”

Citeline’s consulting arm translates its proprietary databases — including EvaluatePharma and Biomedtracker — into actionable insights that help clients identify and prioritize opportunities. The process begins with a “long list to short list” methodology: scanning thousands of assets across therapeutic areas, filtering by scientific feasibility, development phase, and commercial potential, then narrowing to high-value candidates for due diligence.

“The goal,” Keswani said, “is not just to find a partner, but to understand why a partnership makes sense — financially, scientifically, and strategically.”

Inside Citeline’s Strategies: From Data to Decision

Keswani detailed how Citeline integrates analytics with consulting to accelerate global strategies. Its services fall into five key categories:

1. Market Sizing and Forecasting – combining internal datasets with secondary and primary research (KOL interviews, HCP surveys, and patient insights) to create region-specific market projections.
2. Business Development & Licensing Support – asset scouting, partner matching, and license evaluation from both buyer and seller perspectives.
3. Portfolio & Asset Strategy – assessing how political and policy changes, especially in U.S.–China relations, influence pipeline prioritization.
4. Clinical Trial Optimization – benchmarking design feasibility, selecting sites, and predicting enrollment success.
5. Benchmarking and Competitive Intelligence – visual dashboards tracking multi-year deal data, enabling companies to see where their peers are investing and how valuations evolve.

“Our clients want clarity — where the opportunities lie, what’s realistic, and when to move,” Keswani explained. “By combining structured data with contextual analysis, we help them cut through noise and act with confidence.”

Case Study 1: Licensing Opportunities in Dermatology

In one recent assignment, a Japanese client sought to license early-stage dermatology assets to strengthen its growth pipeline. Citeline began by mapping thousands of global candidates using its Biomedtracker and public-domain datasets.

Within four weeks, the team delivered a prioritized top-10 list of attractive assets, filtered by target indication, phase I status, and small-molecule technology. The process included developing concise company profiles and a modular Excel database that the client could update for future scouting.

Beyond identifying names, the real value lay in turning scattered data into a repeatable decision framework. By aligning scoring metrics — clinical promise, differentiation, regulatory path, and market fit — the client could now assess new assets systematically rather than reactively. This structure also clarified when to move: high-ranking programs became immediate outreach targets, while mid-tier candidates entered a “farm lane” for continued monitoring.

“We start by agreeing on objectives, then build the search logic together,” Keswani said. “Our value isn’t just in delivering names — it’s in helping teams understand why those names matter.”

For Japan’s mid-sized pharma, such a framework is transformative. It allows local teams to speak the same analytical language as global partners, accelerating internal alignment and reducing time to first negotiation.

Case Study 2: Benchmarking Global Deal Trends

A second project involved benchmarking five- and ten-year global deal patterns across all therapy areas and modalities. Using Biomedtracker and BioSign DB, Citeline produced both raw datasets and a visualized dashboard that allowed clients to analyze licensing benchmarks by region, phase, and valuation.

The output wasn’t just a retrospective report — it became a live negotiation tool. By showing how similar assets were priced, structured, and performed post-deal, companies could set realistic ask ranges, justify milestone tiers, and defend valuation logic with data. “You can click into any deal and see whether it actually succeeded or failed,” Keswani noted. “That feedback loop helps clients refine their next move — not just imitate what worked once.”

For Japanese firms entering cross-border discussions, such insight is strategic currency. Benchmarking enables term-sheet precision, aligning expectations on upfront payments, co-development structures, and royalty ranges before entering the room. It also builds internal confidence — helping teams move from risk avoidance to informed ambition, grounded in what the market has already validated.

Japan’s Path Forward: Integrating Data, Timing, and Collaboration

For Japan’s pharmaceutical companies, Keswani’s message was clear: the next wave of global competitiveness will be decided by data fluency and timing. The ability to anticipate market shifts, identify emerging modalities, and align resources accordingly will separate leaders from followers.

“Timing and data-driven evaluation are the foundation of good decision-making,” he said in closing. “The companies that succeed will be those that integrate scientific insight with market intelligence — and act before others see the signal.”

His broader implication is that partnership strategy has become a scientific discipline in itself. Just as drug discovery depends on rigorous experimentation, alliance building now requires hypothesis-driven validation supported by real-world evidence.

A Roadmap for the Data-Ready Biotech Era

Keswani’s presentation offered more than analytics — it outlined a roadmap for how Japanese pharma can turn global data into competitive advantage:

1. Adopt a Global Lens Early – evaluate potential partners and markets from day one rather than post-discovery.
2. Invest in Data Literacy – build internal capacity to interpret partnering metrics and benchmarks.
3. Leverage Hybrid Expertise – combine scientific insight with business intelligence for holistic decision-making.
4. Use Scenario Planning – model best- and worst-case outcomes to strengthen negotiation power.
5. Prioritize External Innovation – treat collaboration as a core capability, not a contingency.

In an industry where each partnership can reshape an entire therapeutic area, Japan’s future will depend on connecting its discovery excellence with the world’s data-driven momentum. As Keswani summarized, “Partnerships are no longer about proximity or chance — they’re about precision. And precision comes from data.”

At BIO Japan 2025, the Strategic Global Partnering in BioPharma session showcased how data analytics and evidence-based foresight are redefining how Japanese companies identify, value, and time their next moves in the global market. Image: GeneOnline

Related posts:

From Lab Bench to Global Market: A Practical Playbook for Japan’s Biotech Startups Bridging the Divide: How CRO Partnerships Can Turn Academic Discoveries into Real Drugs One Network, Many Nodes: How Japan’s Drug Discovery Hubs Can Compete Globally in the Next Decade India’s Biotech Shift: From Pharmacy of the World to a $165B Bioeconomy

Author

Bernice Lottering